Evaluating the Patient With Abnormal Liver Tests-2

33
Evaluating the Patient With Abnormal Liver Tests-2 רררר' ררר ררררר רררר ררררר רררר רר רררררר

description

Evaluating the Patient With Abnormal Liver Tests-2. פרופ ' צבי אקרמן מבית חולים הדסה הר הצופים. Imaging studies. Abdominal Ultrasound with Doppler of hepatic and portal veins Abdominal MRCP Upper endoscopy (EGD) Liver biopsy Non Invasive Tests for Fibrosis. Imaging studies-1. - PowerPoint PPT Presentation

Transcript of Evaluating the Patient With Abnormal Liver Tests-2

Page 1: Evaluating the Patient With Abnormal Liver Tests-2

Evaluating the Patient With Abnormal Liver Tests-2

פרופ' צבי אקרמן מבית חולים הדסה הר הצופים

Page 2: Evaluating the Patient With Abnormal Liver Tests-2

Imaging studies

• Abdominal Ultrasound with Doppler of hepatic and portal veins

• Abdominal MRCP

• Upper endoscopy (EGD)

• Liver biopsy

• Non Invasive Tests for Fibrosis

Page 3: Evaluating the Patient With Abnormal Liver Tests-2

Imaging studies-1

• Abdominal Ultrasound with Doppler of hepatic and portal veins-1

• Abdominal ultrasound is helpful in the evaluation of patients with cirrhosis.

• It may reveal a shrunken, nodular liver suggestive of cirrhosis.

Page 4: Evaluating the Patient With Abnormal Liver Tests-2

Imaging studies-1a1a

• The liver may appear echogenic if excessive fat has infiltrated the liver as in NAFLD (nonalcoholic fatty liver disease).

• It is sensitive for the detection of small to moderate amounts of ascites.

• It can be used to screen for liver masses which may suggest the presence of hepatocellular carcinoma.

Page 5: Evaluating the Patient With Abnormal Liver Tests-2
Page 6: Evaluating the Patient With Abnormal Liver Tests-2

Imaging studies-2

• Abdominal Ultrasound with Doppler of hepatic and portal veins-2

• The use of Doppler ultrasonography can provide information about the hepatic and portal veins such as portal vein thrombosis.

• Because it is relatively inexpensive, and widely available, ultrasonography is the preferred initial imaging modality in patients with cirrhosis.

Page 7: Evaluating the Patient With Abnormal Liver Tests-2

Imaging studies-3

• Abdominal MRCP

• MRI is not indicated in every evaluation of liver disease , only in cases where specific bile duct pathology is suspected.

• It is expensive and ‘simple”information can be obtained with ultrasonography.

Page 8: Evaluating the Patient With Abnormal Liver Tests-2

Imaging studies-4

• Upper endoscopy (EGD)

• Upper endoscopy is useful in the diagnosis of esophageal varices, a finding seen with portal hypertension.

• In cirrhotic patients, it is useful to document the presence of varices so prophylactic measures can be instituted to decrease the risk of bleeding.

Page 9: Evaluating the Patient With Abnormal Liver Tests-2

Imaging studies-3

Page 10: Evaluating the Patient With Abnormal Liver Tests-2

Imaging studies-3

Page 11: Evaluating the Patient With Abnormal Liver Tests-2
Page 12: Evaluating the Patient With Abnormal Liver Tests-2

Imaging studies • Abdominal Ultrasound with Doppler of hepatic and

portal veins

• Abdominal MRCP

• Upper endoscopy (EGD)

• Liver fibrosis Assessment :Liver biopsy

• Liver fibrosis Assessment :Non Invasive Tests for Fibrosis

Page 13: Evaluating the Patient With Abnormal Liver Tests-2
Page 14: Evaluating the Patient With Abnormal Liver Tests-2

Liver Biopsy

Hepatic Injury : Hepatic Injury : necrotico-inflammatory activity, necrotico-inflammatory activity, fibrosis, fibrosis, steatosis, steatosis, biliary lesions, vascular lesionsbiliary lesions, vascular lesions

Fibrosis scores Fibrosis scores ( METAVIR, Knodell , Ishak,…)( METAVIR, Knodell , Ishak,…)

  Invasive procedure Invasive procedure  morbidity : 0.3 to 0.6% morbidity : 0.3 to 0.6% mortality : 0 to 0.05% mortality : 0 to 0.05%

Cost : approximately 4000 NIS ( without complications)Cost : approximately 4000 NIS ( without complications)

Page 15: Evaluating the Patient With Abnormal Liver Tests-2
Page 16: Evaluating the Patient With Abnormal Liver Tests-2
Page 17: Evaluating the Patient With Abnormal Liver Tests-2

F1

F4

F2

Page 18: Evaluating the Patient With Abnormal Liver Tests-2

F1

F4

Page 19: Evaluating the Patient With Abnormal Liver Tests-2

Imaging studies

Page 20: Evaluating the Patient With Abnormal Liver Tests-2
Page 21: Evaluating the Patient With Abnormal Liver Tests-2
Page 22: Evaluating the Patient With Abnormal Liver Tests-2

BioMarkers of liver injury

• Markers of Fibrosis

• Scores of Fibrosis

Page 23: Evaluating the Patient With Abnormal Liver Tests-2

Hem orrhage Liver Failure Cancer

F4

F3

F2

F1

F0

Fibrotic LiverDisease

Page 24: Evaluating the Patient With Abnormal Liver Tests-2

How must be an ideal marker of liver Fibrosis?

• Specific to the Liver

• Independant to metabolic dysfunction

• Easy to perform

• Sensitivity to detect the different stages of liver fibrosis

• Can reliably assess the efficacy of antifibrotic treatment

• Can be used whatever the etiology of chonic liver fibrosis

• Non influenced by extra-hepatic factors

Page 25: Evaluating the Patient With Abnormal Liver Tests-2

Haptoglobin

Alpha2Macroglobulin

Apolipoprotein A1

Total Bilirubin

Gamma GT

In Situ In Serum: FibroTestIn Serum: FibroTest

Liver InjuryLiver Injury

Activated Stellate CellsActivated Stellate Cells

Fibrotic MatrixFibrotic Matrix

ALT

Page 26: Evaluating the Patient With Abnormal Liver Tests-2
Page 27: Evaluating the Patient With Abnormal Liver Tests-2

0.00

0.10

0.20

0.30

0.40

0.50

0.60

0.70

0.80

0.90

1.00

0 1 2 3 4

FibroTest

METAVIR Fibrosis Stage

Multicenter Independant ValidationHalfon, Am J Gastroenterol 2006

n=519

Page 28: Evaluating the Patient With Abnormal Liver Tests-2

0.00

0.25

0.50

0.75

1.00

0 1 2 3 4

Fibrosis Stage

Fib

rote

stDisease

HBVHCVHCV_HIVNAFLDOH

Myers et al 2003

Poynard et al 2004

Myers et al 2003

Ratziu et al 2004

Naveau et al 2005

FibroFibroTestTest: fibrosis marker in other chronic : fibrosis marker in other chronic liver diseases (n=2,706)liver diseases (n=2,706)

Page 29: Evaluating the Patient With Abnormal Liver Tests-2

LONGITUDINAL STUDIES

The Fibrotest was found to predict the evolution of HCV patients towards cirrhosis better than liver biopsy after 5 years of follow-upNgo Clin Chem 2006

Page 30: Evaluating the Patient With Abnormal Liver Tests-2

Progression of liver fibrosis

0

1

2

3

4

0 10 20 30 40 50

F METAVIR

Duration in years

Rapid Intermediate

Slow fibroser

Poynard et al

Page 31: Evaluating the Patient With Abnormal Liver Tests-2

Abnormal Liver Test Results: Points for Clinical Practice• Abnormal liver test results will be identified in 8%-20% of patients during

clinical care.

• Most patients with abnormal liver test results should have additional evaluation. A referral to the gastroenterologist may be needed.

• A careful history and physical examination frequently provide the diagnosis, obviating the need for invasive testing.

• If there are signs or symptoms of chronic liver disease, considering the patient's age may assist in the diagnosis.

• Isolated elevation of GGT occurs and a cause may not be identified.

Page 32: Evaluating the Patient With Abnormal Liver Tests-2

CON-Abnormal Liver Test Results: Points for Clinical Practice

• The presence of multiple abnormal test results makes significant liver disease more likely.

• Aminotransferase, alkaline phosphatase, and GGT levels can be elevated from causes other than liver disease.

• Persisting abnormalities of aminotransferases or enzymes of cholestasis should be further evaluated because up to two thirds will have a diagnosis requiring follow-up or intervention.

• Supplemental testing with additional laboratory tests, ultrasonography, or magnetic resonance cholangiography should be considered when the diagnosis is unclear or confirmation of liver disease diagnosis is required.

Page 33: Evaluating the Patient With Abnormal Liver Tests-2

תודה רבה על ההקשבה